Amelenodor (NX-13) is an orally available, gut-selective molecule that activates the mitochondrial receptor NLRX1 to reduce intestinal inflammation. It promotes oxidative phosphorylation while suppressing proinflammatory pathways like Th1/Th17 differentiation and cytokine production. It has the potential to treat inflammatory bowel disease (IBD).

Amelenodor (NX-13) is an orally available, gut-selective molecule that activates the mitochondrial receptor NLRX1 to reduce intestinal inflammation. It promotes oxidative phosphorylation while suppressing proinflammatory pathways like Th1/Th17 differentiation and cytokine production. It has the potential to treat inflammatory bowel disease (IBD).

MCB-22-174 is a potent agonist of Piezo1, with an EC50 value of 6.28 µM. It activates the Ca2+-related extracellular signal-related kinases and calcium–calmodulin (CaM)-dependent protein kinase II (CaMKII) pathway and promotes mesenchymal stem cells osteoblastic differentiation, exhibiting its potential use in research for the treatment of disuse osteoporosis (OP).

Semustine is a member of the chloroethyl nitrosourea (CENU) family that induces DNA alkylation at the major groove, forming interstrand cross-links between guanine and cytosine bases (dG-dC). It exerts antitumor activity by inducing these DNA cross-links and is used as an antineoplastic alkylating agent for treating Lewis lung carcinoma, leukemia, and metastatic brain tumors.

Amelenodor (NX-13) is an orally available, gut-selective molecule that activates the mitochondrial receptor NLRX1 to reduce intestinal inflammation. It promotes oxidative phosphorylation while suppressing proinflammatory pathways like Th1/Th17 differentiation and cytokine production. It has the potential to treat inflammatory bowel disease (IBD).

Amelenodor (NX-13) is an orally available, gut-selective molecule that activates the mitochondrial receptor NLRX1 to reduce intestinal inflammation. It promotes oxidative phosphorylation while suppressing proinflammatory pathways like Th1/Th17 differentiation and cytokine production. It has the potential to treat inflammatory bowel disease (IBD).

Semustine is a member of the chloroethyl nitrosourea (CENU) family that induces DNA alkylation at the major groove, forming interstrand cross-links between guanine and cytosine bases (dG-dC). It exerts antitumor activity by inducing these DNA cross-links and is used as an antineoplastic alkylating agent for treating Lewis lung carcinoma, leukemia, and metastatic brain tumors.

Semustine is a member of the chloroethyl nitrosourea (CENU) family that induces DNA alkylation at the major groove, forming interstrand cross-links between guanine and cytosine bases (dG-dC). It exerts antitumor activity by inducing these DNA cross-links and is used as an antineoplastic alkylating agent for treating Lewis lung carcinoma, leukemia, and metastatic brain tumors.

Semustine is a member of the chloroethyl nitrosourea (CENU) family that induces DNA alkylation at the major groove, forming interstrand cross-links between guanine and cytosine bases (dG-dC). It exerts antitumor activity by inducing these DNA cross-links and is used as an antineoplastic alkylating agent for treating Lewis lung carcinoma, leukemia, and metastatic brain tumors.

FOT1 (CN128, CN328) hydrochloride is a potent and orally active hydroxypyridinone iron chelator with potential for treating systemic iron overload and β-thalassemia. It also helps prevent the onset and slows early-stage Parkinson’s disease symptoms by reducing oxidants and toxic intermediates from iron-mediated dopamine oxidation.